Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19%...
Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...
Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has assumed exclusive licensing rights from...
Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit
Suzhou Basecare Medical Co., Ltd. (HKG: 2170) announced that China’s National Medical Products Administration (NMPA)...
HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia
HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that China’s National Medical Products Administration (NMPA)...
Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
Novartis AG (NYSE: NVS) reported Q1 2026 financial results showing USD 13.1 billion in net...
Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion
Astellas Pharma Inc. (TYO: 4503) reported FY2025 financial results showing JPY 2,139.2 billion (USD 13.9...
Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results...
Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets
Fosun Pharma (SHA: 600196; HKG: 2196) announced it has signed a Memorandum of Cooperation with...
Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has...
Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced a strategic partnership with Sun...
Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform
Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance and...
Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801
Vivacta Biotechnology, a Shanghai-based in vivo chimeric antigen receptor (CAR)-T therapy developer, announced the successful...
Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis
Insilico Medicine (HKG: 3696), a generative artificial intelligence (AI)-driven biotechnology company, announced it has received...
Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported Q1 2026 financial results showing RMB...
Immunotech Biopharm’s EAL Cellular Therapy Rejected by NMPA; Confirmatory Trials Required
Immunotech Biopharm Ltd. (HKG: 6978), a chimeric antigen receptor T-cell (CAR-T) specialist based in China,...
GluBio Pharmaceutical Advances GLB-002 Molecular Glue Degrader to Phase II for Relapsed Follicular Lymphoma
GluBio Pharmaceutical Co., Ltd., a molecular glue targeted protein degradation (TPD) specialist based in Zhejiang,...
Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received marketing authorization from the European...
AbbVie Submits FDA Application for RINVOQ in Severe Alopecia Areata – Expanding JAK Inhibitor Franchise
AbbVie Inc. (NYSE: ABBV) announced the submission of a supplemental New Drug Application (sNDA) to...
Medtronic Secures CE Mark for Stealth AXiS Surgical System – Next-Generation Integrated Robotics Platform
Medtronic plc (NYSE: MDT) announced it has received CE Mark approval for the Stealth AXiS...